81.8% of patients with bothersome tinnitus treated with Lenire at New York Hearing Doctors reported significant improvement in a real-world clinical setting.1,2 Patients with bothersome tinnitus reported a 23.8 point mean reduction in tinnitus as measured by the Tinnitus Handicap Inventory, which is greater than three times the threshold for clinical significance.1,2 The majority of patients with bothersome tinnitus reported they were no longer severely impacted by their tinnitus following 12-

UPPSALA, Sweden, Feb. 17, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced that it, together with leading glioblastoma researchers at KU Leuven, has been awarded a EUR 2.5 million grant by the European Innovation Council (EIC) to advance a precision immune therapy for glioblastoma, the most common and aggressive brain tumour which currently lacks effective treatment. In the project GLIOBREAK, Beactica and KU Leuven are joining forces to advance

MILAN, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”, or the “Company”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it has entered into an agreement for the subscription of newly issued shares for proceeds of up to EUR 38 million with a group of existing and new shareholders from Europe and Asia, strengthening th

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on previous results for selpercatinib in advanced NSCLC and reinforce the value of genomic testing at diagnosis and across all stages of disease INDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 LIBRETTO-432 clinical tri

Roche announced Monday that a Phase III study of Gazyva/Gazyvaro (obinutuzumab) in adults with primary membranous nephropathy met its primary endpoint, potentially setting up another approval for the anti-CD20 monoclonal antibody and the first for a therapy in this chronic autoimmune condition.The MAJESTY trial randomised 142 people with primary membranous nephropathy to receive Gazyva/Gazyvaro or tacrolimus. Results showed that significantly more people achieved complete remission at week 104 w

– MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years – – Up to 30% of people with membranous nephropathy progress to kidney failure over 10 years despite current treatment approaches; achieving complete remission can help delay or prevent this – – Gazyva could become the first approved treatment for primary membranous nephropathy, having already achieved positive results in lupus nephritis, systemic lupus eryth

The proceeds will be used for completing ongoing Phase III ENSURE trials for vidofludimus calcium in RMS. Credit: Gorodenkoff / Shutterstock.com. Immunic has announced an oversubscribed private placement of up to $400m, strengthening its move from an R&D-focused organisation into a commercial-stage entity. The placement was led by existing investor BVF Partners and joined by entities such as Avidity Partners, OrbiMed, Trails Edge Capital Partners, TCGX, Vivo Capital and other institutional inves

HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntington’s disease Clinical Advisory Board formed to support progression of HRN001 into first-in-human studies in 2027 Dr Andy Billinton, CSO will present preclinical data at the upcoming CHDI Foundation Huntington’s Disease Therapeutics Conference Cambridge, UK, 16 February 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking pr

GLP-1 initiation is associated with a 14.6% reduced risk of asthma exacerbation for overweight patients, 12.2% for obese patients and 13.3% for morbidly obese patients MILWAUKEE, Feb. 15, 2026 /PRNewswire/ -- Glucagon-like peptide-1 receptor agonists (GLP-1) is linked to a significant reduction in asthma exacerbations for overweight, obese and morbidly obese patients without diabetes, according to new research being presented at the 2026 AAAAI Annual Meeting. "Asthma exacerbations can be disrupt

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global development of this innovative immunotherapy. The ongoing global multicenter Phase II trial is currently enrolling patients in Australia and China. The study design includes 15 cohorts evaluating both monotherapy and co